Stock analysts at UBS Group assumed coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a report issued on Monday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Wells Fargo & Company restated a “buy” […]
Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) – Equities research analysts at SVB Leerink issued their Q2 2022 earnings per share (EPS) estimates for Horizon Therapeutics Public in a note issued to investors on Sunday, May 22nd. SVB Leerink analyst D. Risinger forecasts that the biopharmaceutical company will post earnings per share of $1.33 […]
Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) CEO Timothy P. Walbert sold 25,000 shares of the stock in a transaction that occurred on Friday, May 20th. The stock was sold at an average price of $90.00, for a total value of $2,250,000.00. Following the transaction, the chief executive officer now directly owns 460,549 shares […]
Analysts expect Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) to post $882.96 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Horizon Therapeutics Public’s earnings. The lowest sales estimate is $860.21 million and the highest is $941.30 million. Horizon Therapeutics Public posted sales of $342.41 million […]
Wells Fargo & Company reissued their buy rating on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a research report report published on Friday, TipRanks reports. The firm currently has a $133.00 price target on the biopharmaceutical company’s stock. Several other analysts also recently commented on HZNP. Piper Sandler lowered their target price […]